Skip to main content
. 2016 Sep 18;2016(9):CD006992. doi: 10.1002/14651858.CD006992.pub2

Sato 2015.

Methods 24‐week, prospective, randomised, open‐labelled, controlled trial
Participants Participants with type 2 diabetes who were suboptimally controlled despite receiving at least twice‐daily injections of insulin were enrolled in the trial
Interventions The participants were randomised to continuation of insulin treatment (insulin group) or addition of sitagliptin 50 mg‐100 mg daily to insulin treatment
Outcomes HbA1c, body weight, hypoglycaemia, treatment satisfaction
Notes